Fulcrum Therapeutics, Inc. (FULC)
Market Cap | 217.37M |
Revenue (ttm) | 80.87M |
Net Income (ttm) | -17.91M |
Shares Out | 53.94M |
EPS (ttm) | -0.29 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 856,276 |
Open | 4.250 |
Previous Close | 4.270 |
Day's Range | 3.940 - 4.280 |
52-Week Range | 2.860 - 13.700 |
Beta | 2.11 |
Analysts | Hold |
Price Target | 7.44 (+84.62%) |
Earnings Date | Nov 13, 2024 |
About FULC
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discove... [Read more]
Financial Performance
In 2023, Fulcrum Therapeutics's revenue was $2.81 million, a decrease of -55.77% compared to the previous year's $6.34 million. Losses were -$97.34 million, -11.41% less than in 2022.
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for FULC stock is "Hold." The 12-month stock price forecast is $7.44, which is an increase of 84.62% from the latest price.
News
Fulcrum Therapeutics to Participate in Upcoming December Conferences
CAMBRIDGE, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to impr...
Fulcrum Therapeutics, Inc. (FULC) Q3 2024 Earnings Call Transcript
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q3 2024 Earnings Conference Call November 13, 2024 8:00 AM ET Company Participants Alex Sapir - President and Chief Executive Officer Alan Musso - Chief Finan...
Fulcrum Therapeutics to Participate in the Stifel Healthcare Conference
CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to impro...
Fulcrum Therapeutics to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, November 13, 2024 at 8:00 a.m. ET
CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to impr...
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of...
FMR LLC's Strategic Reduction in Fulcrum Therapeutics Inc Shares
On September 30, 2024, FMR LLC (Trades, Portfolio) executed a significant transaction involving the sale of 3,605,932 shares in Fulcrum Therapeutics Inc (FULC, Financial), a clinical-stage biopharmace...
Investors Are Invited To Join The Schall Law Firm In An Inquiry Into Fulcrum Therapeutics Inc For Possible Securities Fraud
LOS ANGELES, CA / ACCESSWIRE / October 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Fulcrum Therape...
Fulcrum Therapeutics, Inc. Is Being Investigated For Violating Securities Laws And The Schall Law Firm Urges Shareholder Participation
LOS ANGELES, CA / ACCESSWIRE / October 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Fulcrum Therape...
Investors Are Encouraged To Join The Schall Law Firm In An Inquiry Into Fulcrum Therapeutics Inc For Possible Securities Fraud
LOS ANGELES, CA / ACCESSWIRE / September 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Fulcrum Ther...
Fulcrum Therapeutics, Inc. Is Being Investigated For Securities Law Violations And The Schall Law Firm Invites Shareholders With Losses To Help
LOS ANGELES, CA / ACCESSWIRE / September 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Fulcrum Ther...
The Schall Law Firm Is Looking Into Whether Fulcrum Therapeutics Inc Committed Securities Fraud And Impacted Investors Should Reach Out
LOS ANGELES, CA / ACCESSWIRE / September 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Fulcrum Ther...
Shareholders Are Encouraged To Join The Schall Law Firm's Inquiry Into Fulcrum Therapeutics, Inc. For Violating Securities Laws
LOS ANGELES, CA / ACCESSWIRE / September 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Fulcrum Ther...
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Fulcrum Therapeutics, Inc. (FULC) And Encourages Shareholders to Reach Out
NEW YORK, NY / ACCESSWIRE / September 27, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company")...
Fulcrum Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Investors To Lend A Hand
LOS ANGELES, CA / ACCESSWIRE / September 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Fulcrum Ther...
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Fulcrum Therapeutics, Inc. (FULC) and Encourages Shareholders to Learn More About the Investigation
NEW YORK, NY / ACCESSWIRE / September 26, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company")...
The Schall Law Firm Is Looking Into Fulcrum Therapeutics, Inc. For Possible Securities Law Violations And Shareholders Are Invited To Participate
LOS ANGELES, CA / ACCESSWIRE / September 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Fulcrum Ther...
Fulcrum Therapeutics, Inc. (FULC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
NEW YORK, NY / ACCESSWIRE / September 25, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company")...
Fulcrum Therapeutics Inc May Have Defrauded The Public And Affected Investors Should Join The Schall Law Firm's Inquiry
LOS ANGELES, CA / ACCESSWIRE / September 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Fulcrum Ther...
Bronstein, Gewirtz & Grossman, LLC Encourages Fulcrum Therapeutics, Inc. (FULC) Shareholders to Inquire about Securities Investigation
NEW YORK, NY / ACCESSWIRE / September 24, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company")...
The Schall Law Firm Is Investigating Fulcrum Therapeutics, Inc. For Possible Securities Law Violations And Stockholders With Losses Are Urged To Reach Out
LOS ANGELES, CA / ACCESSWIRE / September 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Fulcrum Ther...
Fulcrum Therapeutics, Inc. (FULC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation!
NEW YORK, NY / ACCESSWIRE / September 23, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company")...
Fulcrum Therapeutics Inc May Have Engaged In Securities Fraud And The Schall Law Firm Encourages Affected Investors To Join An Inquiry
LOS ANGELES, CA / ACCESSWIRE / September 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Fulcrum Ther...
Bronstein, Gewirtz & Grossman, LLC Is Investigating Fulcrum Therapeutics, Inc. (FULC) And Encourages Investors to Connect
NEW YORK, NY / ACCESSWIRE / September 22, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company")...
The Schall Law Firm Is Investigating Whether Fulcrum Therapeutics, Inc. Violated Securities Laws And Stockholders With Losses Are Invited To Reach Out
LOS ANGELES, CA / ACCESSWIRE / September 21, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Fulcrum Ther...
Fulcrum Therapeutics Inc Is Being Looked Into For Securities Fraud And The Schall Law Firm Seeks Impacted Shareholders To Join The Inquiry
LOS ANGELES, CA / ACCESSWIRE / September 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Fulcrum Ther...